Tablet Presentation

Each film coated tablets contains:

Cefpodoxime Proxetil IP           200 mg Dicloxacillin Sodium {ER} IP   500 mg

CEFPODOXIME PROXETIL is an extended spectrum,third generation cephalosporin antibiotic. Bactericidal - Arrests the cell wall assembly leading to bacterial cell death.

DICLOXACILLIN SODIUM {ER} is a narrow-spectrum beta-lactam antibiotic of the penicillin class. It is used to treat infections caused by susceptible Gram-positive bacteria. It is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins.

Indications

• For the treatment of lower RI,Skin and soft tissue,bone and joint infections and ENT infections in adult prone to antibiotic induced diarrhoea.

Description

This combination of cephalosporin (potent activity against gram (-ve) strains) and Beta - lactamase resistant penicillin (dicloxacillin) with MIC value of =0.06 (ug / ml) for S. pneumoniae, 0.5 - >16 mg/ml for P.aeruginosa, 0.05-2 (ug/ml) for S. aureus, = 0.06-2 for H. influenzae and = 0.06 for E. coil makes it a broad spectrum antibiotic. Safe and well - tolerated in adults and children. Moreover, this combination has a wide distribution pattern throughout the body, distributed into blister fluid, interstitial fluid, middle ear fluid, tonsils, maxillary sinus mucosa, bronchial mucosa, pleural fluid, lung tissue, epithelial lining fluid, myometrium, seminal fluid, prostatic adenoma tissue, and bile which allows its use in variable disease conditions.

Advantages

MIC value of Amoxycillin clavulanate against S. pneumoniae is = 2ug/ml whereas cefpodoxime dicloxacillin combination MIC against same is = 0.5 ug.ml which proves it a better medication for pneumonia. Moreover Amoxycillin clavalunate combination is not efficacious against Pseudomonas infections while cefpodoxime and dicloxacillin combination is effective with MIC value 0.5 -> 16. Pseudomonas species causes skin infections (such as burns and pressure ulcers), urinary tract infections (UTIs), infant epidemic diarrhoea and other diarrhoeal illnesses, bronchitis, pneumonia, meningitis, otitis externa, otitis media, endocarditis, and bacteremia. In addition cefpodoxime dicloxacillin combination has a higher mean bone and serum concentrations with greater microbiological efficacy than amoxicillin clavalunate combination which allows for its tremendous effectiveness in bone and joint infections. The severity of side effects as shown by following table also suggests better efficacy of cefpodoxome dicloxacillin as compared to amoxicillin clavulanate combination.

	DIARROHEA	RASH	Gastrtrointestinal side effects
CEFPODOXIME + DICLOXACILLIN	6%	<1%	8 - 10 %
AMOXYCILLIN CLAVALUNATE	9%	3%	21.1%

CEFPODOXIME + DICLOXACILLIN HAS GOOD EFFICACY AGAINST BACTERIAL STRAINS RESISTANT TO AZITHROMYCIN (FOR OTHER BACTERIAL INFECTIONS)

Recently an outbreak of a strain of Group A streptococcus, the bacterium responsible for strep throat and a number of other infections, that is resistant to the commonly prescribed antibiotic erythromycin as well to other drugs in the same class eg azithromycin has been reported. Whereas Cefpodoxime has proved to be highly inhibitory against group A, B and G streptococcl (with MIC90 less than 0.015 mg/l).

CONCLUSION

CEFPODOXIME DICLOXACILLIN HAS PROOVED TO BE A BETTER AND EFFICACOUS COMBINATION IN THE TREATMENT OF:

• Lower respiratory tract infections like pneumonia, bronchitis, lung abcess, etc.
• Skin and soft tissue infections like abscesses, furuncles ("boils"), and carbuncles.
• Bone and joint infections like osteomyelitis, septic arthritis, etc.
• ENT infections like strep throat, tonsillitis, sinusitis, otitis media, etc.